Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 58-65

  Kallmann, Boris A ^a,b   Fackelmann, S ^a   Toyka, K V ^a   Rieckmann, P ^a   Reiners, K ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Evoked potentials; Multiple sclerosis; Predictors of disability

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DETERIORATION; DIAGNOSTIC VALUE; DISABILITY; DISEASE DURATION; EVOKED MUSCLE RESPONSE; EVOKED RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGE OF ONSET; DISABLED PERSONS; DISEASE PROGRESSION; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; EVOKED POTENTIALS, MOTOR; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 31644434214     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1244oa     Document Type: Article

References (22)

1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
2. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
3. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 2002; 59: S1-33.
4. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43: 79-87.
5. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45: 1277-85.
6. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64.
7. O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503.
8. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1720-25.
9. Hume AL, Waxman SG. Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of clinical course. J Neurol Sci 1988; 83: 191-210.
10. Beer S, Rosler KM, Hess CW. Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria. J Neurol Neurosurg Psychiatry 1995; 59: 152-59.
11. O'Connor P, Marchetti P, Lee L, Perera M. Evoked potential abnormality scores are a useful measure of disease burden in relapsing - remitting multiple sclerosis. Ann Neurol 1998; 44: 404-407.
12. Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001; 124: 2162-68.
13. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-28.
14. Poser CM, Paty DW, Scheinberg L, MacDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
16. Deuschl G, Eisen A. Recommendations for the practice of clinical neurophysiology: guidelines of the International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol 1999; 52 (Supplement).
17. Miura. T, Sonoo M, Shimizu T. Establishment of standard values for the latency, interval and amplitude parameters of tibial nerve somatosensory evoked potentials (SEPs). Clin Neurophysiol 2003; 114: 1367-78.
18. Meyer BU, Britton TC, Benecke R, Bischoff C, Machetanz J, Conrad B. Motor responses evoked by magnetic brain stimulation in psychogenic limb weakness: diagnostic value and limitations. J Neurol 1992; 239:251-55.
19. Salle JY, Hugon J, Tabaraud F, Boulesteix JM, Vallat JM, Dumas M et al. Improvement in motor evoked potentials and clinical course post-steroid therapy in multiple sclerosis. J Neurol Sci 1992; 108: 184-88.
20. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-38.
21. Matthews WB, Wattam-Bell JR, Pountney E. Evoked potentials in the diagnosis of multiple sclerosis: a follow up study. J Neurol Neurosurg Psychiatry 1982; 45: 303-307.
22. Chiappa KH. Pattern shift visual, brainstem auditory, and short-latency somatosensory evoked potentials in multiple sclerosis. Neurology 1980; 30: 110-23.